EU Off-Patent Industry Sees ‘Limited Immediate Risk’ From COVID-19
But Coronavirus Could Have ‘Important Impact’ If Situation Continues
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.
